Current studies of novel drugs against hepatitis B virus in clinical trials
10.3969/j.issn.1001-5256.2016.02.038
- VernacularTitle:临床试验阶段抗HBV新药的研究现状
- Author:
Qiang LI
1
;
Yuxian HUANG
;
Liang CHEN
Author Information
1. First Department of Hepatitis, Public Health Clinical Center Affiliated to Fudan University, Shanghai 201508, China
- Publication Type:Research Article
- Keywords:
hepatitis B virus;
antiviral agents;
clinical trial;
review
- From:
Journal of Clinical Hepatology
2016;32(2):370-373
- CountryChina
- Language:Chinese
-
Abstract:
Chronic hepatitis B (CHB) is one of the major causes of liver cirrhosis and hepatocellular carcinoma. Interferon and nucleos(t)ide analogues can control disease progression. However, they cause very low HBsAg clearance or seroconversion rates and relapse in most patients after treatment withdrawal. In recent years, the further understanding of the interaction between hepatitis B virus (HBV) and host gives birth to a large number of novel drugs that hold promise for successful cure of CHB. This paper reviews several novel drugs against HBV in phase Ⅰ, Ⅱ, or Ⅲ clinical trials, and points out that these novel drugs against HBV have preliminarily indicated a bright future.
